Eldelumab [anti-interferon-γ-inducible protein-10 antibody] Induction Therapy for Active Crohn's Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study.
about
Circulating miR-125a but not miR-125b is decreased in active disease status and negatively correlates with disease severity as well as inflammatory cytokines in patients with Crohn's disease.Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Bowel Disease; Pitfalls and Promise
P2860
Eldelumab [anti-interferon-γ-inducible protein-10 antibody] Induction Therapy for Active Crohn's Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Eldelumab [anti-interferon-γ-i ...... bo-controlled Phase IIa Study.
@en
type
label
Eldelumab [anti-interferon-γ-i ...... bo-controlled Phase IIa Study.
@en
prefLabel
Eldelumab [anti-interferon-γ-i ...... bo-controlled Phase IIa Study.
@en
P2093
P2860
P50
P356
P1476
Eldelumab [anti-interferon-γ-i ...... bo-controlled Phase IIa Study.
@en
P2093
Allison Luo
Bruce E Sands
Pranab Mitra
Robert Petryka
Subrata Ghosh
P2860
P356
10.1093/ECCO-JCC/JJX005
P577
2017-02-22T00:00:00Z